2026out.
BSX Oct 2026 · Strong Buy
Boston Scientific Corporation presents a compelling investment thesis underpinned by category-leading cardiovascular franchises, robust international procedural expansion, and multi-year margin expansion initiatives. The house rating is Strong Buy. Market pricing reflects heightened concern over near-term product mix headwinds in WATCHMAN and temporary electrophysiology competitive noise, discounting a multi-year recovery powered by pulsed field ablation ecosystem expansion, SEISMIQ IVL scale, and a $500M enterprise efficiency program,.Latest published research · analyzed 2026-10-22 · current · sources aging